- All sections
- C - Chemistrymetallurgy
- C07K - Peptides
- C07K 14/715 - ReceptorsCell surface antigensCell surface determinants for cytokinesReceptorsCell surface antigensCell surface determinants for lymphokinesReceptorsCell surface antigensCell surface determinants for interferons
Patent holdings for IPC class C07K 14/715
Total number of patents in this class: 2831
10-year publication summary
|
98
|
172
|
153
|
190
|
226
|
227
|
269
|
264
|
233
|
53
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Regeneron Pharmaceuticals, Inc. | 4570 |
103 |
| Altor BioScience, LLC | 78 |
56 |
| Xencor, Inc. | 406 |
43 |
| The United States of America, as represented by the Secretary, Department of Health and Human Services | 2956 |
38 |
| Immunitybio, Inc. | 491 |
34 |
| The Trustees of the University of Pennsylvania | 4392 |
33 |
| The Board of Trustees of the Leland Stanford Junior University | 6593 |
31 |
| National University of Singapore | 2551 |
27 |
| Vib VZW | 887 |
26 |
| Cytune Pharma | 39 |
25 |
| The Regents of the University of California | 20473 |
24 |
| FATE Therapeutics, Inc. | 225 |
24 |
| Synthekine, Inc. | 118 |
24 |
| Amgen Inc. | 4327 |
23 |
| Dana-Farber Cancer Institute, Inc. | 2622 |
23 |
| Universiteit Gent | 1370 |
23 |
| Singapore Health Services Pte Ltd | 482 |
23 |
| Novartis AG | 10376 |
21 |
| Autolus Limited | 265 |
21 |
| Institut National de La Sante et de La Recherche Medicale (inserm) | 3110 |
19 |
| Other owners | 2190 |